109820 — GENEMATRIX Balance Sheet
0.000.00%
- KR₩48bn
- KR₩50bn
- KR₩10bn
Annual balance sheet for GENEMATRIX, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 12,212 | 12,479 | 4,798 | 2,135 | 1,828 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 2,694 | 6,238 | 13,227 | 14,264 | 14,577 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 19,062 | 21,113 | 21,280 | 19,405 | 19,568 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 6,318 | 6,168 | 6,325 | 6,442 | 6,014 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 38,168 | 39,532 | 31,902 | 31,354 | 28,458 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4,082 | 5,343 | 5,006 | 4,519 | 4,704 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 4,775 | 7,211 | 7,717 | 8,206 | 9,231 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 33,393 | 32,321 | 24,186 | 23,148 | 19,227 |
Total Liabilities & Shareholders' Equity | 38,168 | 39,532 | 31,902 | 31,354 | 28,458 |
Total Common Shares Outstanding |